Antidepressant: Difference between revisions
imported>Robert Badgett (Started 'See also') |
imported>Robert Badgett (Started "Adverse effects") |
||
| Line 14: | Line 14: | ||
[[Monoamine oxidase inhibitor]]s are a "chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines".<ref>{{MeSH|Monoamine Oxidase Inhibitors}}</ref> | [[Monoamine oxidase inhibitor]]s are a "chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines".<ref>{{MeSH|Monoamine Oxidase Inhibitors}}</ref> | ||
==Adverse effects== | |||
===Neuroleptic malignant syndrome=== | |||
{{main|Neuroleptic malignant syndrome}} | |||
===Serotonin syndrome=== | |||
{{main|serotonin syndrome}} | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 09:24, 2 April 2008
Antidepressant medications are "mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several monoamine oxidase inhibitors are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (tricyclic antidepressant) also appear to act through brain catecholamine systems. A third group (second-generation antidepressant agents) is a diverse group of drugs including some that act specifically on serotonergic systems."[1]
Classification
Second-generation antidepressants
Second-generation antidepressants are a "structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake."[2]
Tricyclic antidepressants
Tricyclic antidepressants are "substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system."[3]
Monoamine oxidase inhibitors
Monoamine oxidase inhibitors are a "chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines".[4]
Adverse effects
Neuroleptic malignant syndrome
Serotonin syndrome
References
- ↑ Anonymous (2024), Antidepressant (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Second-generation antidepressants (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Tricyclic Antidepressive Agents (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Monoamine Oxidase Inhibitors (English). Medical Subject Headings. U.S. National Library of Medicine.